@article{Gonzalez_Dorta_H-2025_209407,
title = {Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study},
author = {Gonzalez Dorta, H. and Verbeeck, J. and Crevecoeur, J. and Loedy, N. and Cohet, C. and Willem, L. and Molenberghs, G. and Hens, N. and Kurz, X. and Quinten, C. and Abrams, S. and Morales, D.},
month = {apr},
year = {2025},
abstract = {BACKGROUND: Several COVID-19 vaccines have been licensed. To support the assessment of safety signals, we developed a toolkit to support COVID-19 vaccine monitoring and benefit-risk assessment. We aim to show the application of our toolkit in the EU using thrombosis with thrombocytopenia syndrome (TTS) associated with the Vaxzevria (AstraZeneca) vaccine as a use case.},
volume = {7},
issue = {5},
journal = {The Lancet Digital Health},
publisher = {Elsevier},
url = {https://doi.org/10.1016/j.landig.2025.02.001},
}
